Muņoz, Delicias <br/><br/>
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.  [electronic resource] 

 -  BMC neurology  Jul 2013 
 - 82 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2377 
<br/><br/><label>Standard No.: </label>10.1186/1471-2377-13-82  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2',5'-Oligoadenylate Synthetase--metabolism<br/>Body Mass Index<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunologic Factors--adverse effects<br/>Interferon-beta--adverse effects<br/>Kaplan-Meier Estimate<br/>Male<br/>Multiple Sclerosis, Chronic Progressive--drug therapy<br/>Neopterin--metabolism<br/>Predictive Value of Tests<br/>Retrospective Studies<br/>Treatment Outcome<br/>beta 2-Microglobulin--metabolism